Letermovir and Belumosudil: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 15, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Letermovir
Belumosudil
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Letermovir (Prevymis) slows down a liver enzyme called CYP3A that helps break down many medicines. Belumosudil (Rezurock) is one of those medicines. So when you take them together, your body clears belumosudil more slowly, and the amount in your blood can go up. That can mean stronger effects and a higher chance of side effects.
The good news is this is very manageable. Your care team may keep a closer eye on how you're feeling and can adjust your belumosudil dose if needed. Please don't stop or change either medicine on your own. Just check in with your pharmacist or doctor so they can tailor things for you.
Mechanism: Letermovir is a moderate CYP3A inhibitor. Belumosudil is a CYP3A substrate, so its metabolism is reduced, increasing systemic exposure (AUC/Cmax).
Direction: Increased belumosudil exposure and potential for enhanced effect/toxicity.
- Magnitude: Not directly studied for belumosudil; letermovir raised oral midazolam AUC ~125% and Cmax ~72% as an index substrate.
- Onset: Unspecified.
- Evidence: Probable.
- Management: Anticipate increased exposure; dose may need individualization and closer clinical monitoring for belumosudil-related adverse effects. Review product labeling for CYP3A-inhibitor guidance.
What happens
Increased CYP3A substrate exposure
Interaction Deep Dive
When letermovir is taken together with a CYP3A substrate, exposure to that substrate can rise. One drug interaction study examined this using midazolam as the CYP3A substrate. Giving letermovir (240 mg orally once daily) alongside a single 1 mg IV dose of midazolam raised the midazolam AUC by 47%, its Cmax by 5%, and its C24hr by 174%. In addition, when letermovir (240 mg orally once daily) was given with a single 2 mg oral dose of midazolam, the midazolam AUC increased by 125% and its Cmax by 72%1.
Why it happens (mechanism)
Inhibition of CYP3A-substrate metabolism by letermovir
How to manage this interaction
What your care team may do:
- Watch you more closely for belumosudil side effects while you're on both drugs.
- Adjust and individualize your belumosudil dose if they feel it's needed.
- Consider timing or alternatives based on your full medication list.
What you can do:
- Keep taking both medicines exactly as prescribed unless told otherwise.
- Tell your pharmacist or doctor about any new or worse side effects.
- Make sure your care team knows you take both, so they can tailor your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In a study of drug interactions, giving letermovir (240 mg orally once daily) together with a CYP3A substrate, midazolam (a single 1 mg IV dose), raised the AUC, Cmax and C24hr of midazolam by 47%, 5% and 174%, respectively. Additionally, giving letermovir (240 mg orally once daily) together with midazolam (a single 2 mg oral dose) raised the AUC and Cmax of midazolam by 125% and 72%, respectively 1.
Common questions
Can I take Letermovir and Belumosudil together?
Letermovir can raise belumosudil levels by slowing its breakdown, so your team may monitor you more closely and adjust the belumosudil dose. Keep taking both as prescribed and report any new side effects. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Letermovir and Belumosudil interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Letermovir and Belumosudil interaction managed?
What your care team may do: Watch you more closely for belumosudil side effects while you're on both drugs. Adjust and individualize your belumosudil dose if they feel it's needed. Consider timing or alternatives based on your full medication list. What you can do: Keep taking both medicines exactly as prescribed unless told otherwise. Tell your pharmacist or doctor about any new or worse side eff… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Letermovir or Belumosudil need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: PREVYMIS(R) oral tablets, oral pellets, intravenous injection, letermovir oral tablets, oral pellets, intravenous injection. Merck Sharp & Dohme Corp (per FDA), Rahway, NJ, 2024. DailyMed
Keep reading about Letermovir
Keep reading about Belumosudil
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist